Angle Plc - ANPCY STOCK NEWS

ANGLE plc (OTCQX:ANPCY) has issued 26,667 new ordinary shares following the exercise of employee options, increasing the total shares to 234,208,051. The new shares will begin trading on the London Stock Exchange on 9 August 2021. ANGLE is renowned for its liquid biopsy technology, the Parsortix system, which allows non-invasive cancer cell analysis and has shown significant accuracy in clinical studies, particularly for ovarian cancer. The company is pursuing FDA clearance for its system, aiming to enhance its market position in oncology diagnostics.

ANGLE plc has secured a pharma services contract for developing two custom CTC assays targeting DNA damage repair biomarkers. The contract, valued at approximately US$ 400,000, involves developing assays for four challenging cancers: triple negative breast cancer, prostate cancer, ovarian cancer, and pancreatic cancer. The initial phase will provide significant revenue and, if successful, will lead to further clinical trials planned for H2 2022. The assays will enhance ANGLE's service offerings to pharma clients by enabling targeted analysis on circulating tumor cells.

ANGLE plc (OTCQX:ANPCY) announces significant advancements using its Parsortix system to isolate circulating tumor cells (CTCs) from patients with brain metastasis. This breakthrough offers a non-invasive alternative to traditional tissue biopsies for patients with breast cancer, non-small cell lung cancer, and melanoma, achieving 50% CTC positivity rates in breast and NSCLC patients, outperforming previous technologies. With approximately 200,000 new brain metastasis cases in the US annually, this method could enhance personalized treatment decisions and improve patient outcomes.

ANGLE plc announces the allotment of 1,023,826 new ordinary shares following the exercise of options by CEO Andrew Newland. The shares were sold at 125 pence each for personal financial reasons. After the sale, Newland retains 7,054,686 shares, equating to 3.0% of the total issued share capital, alongside options for an additional 3,000,000 shares and up to 5,400,000 through performance plans. The total number of shares in issue will rise to 234,181,384 upon the new shares' admission on July 14, 2021.

ANGLE plc (AIM:AGL OTCQX:ANPCY), a leader in liquid biopsy technology, has issued 48,333 new Ordinary shares due to employee option exercises. This issuance increases the total shares to 233,157,558, enhancing voting rights. The shares are expected to be admitted to trading on the London Stock Exchange on July 7, 2021. ANGLE's Parsortix technology continues to gain traction, with ongoing FDA submission for CTC analysis in breast cancer and strong clinical performance in ovarian cancer diagnostics.

ANGLE plc announced the results of its Annual General Meeting held on June 30, 2021, where all resolutions were passed. The company, known for its innovative liquid biopsy technology, is progressing with the Parsortix system, which has received CE Mark approval in Europe and is awaiting FDA clearance in the U.S. for metastatic breast cancer applications. ANGLE's ongoing clinical studies show promising results, including a recent ovarian cancer test with an accuracy rate of 95.1%. Their technology aims to enhance cancer diagnostics through non-invasive methods.

ANGLE plc (AIM:AGL OTCQX:ANPCY) announces its Annual General Meeting (AGM) will take place on June 30, 2021, at 2:00 PM in Guildford, UK, as a closed meeting due to COVID-19 restrictions. Only two shareholders are required for a quorum, with executive members attending in person and others remotely. Voting will be online via proxy, and shareholders must register in advance to attend online. A business update will follow the AGM, and questions can be submitted to the Board in advance. The Annual Report was distributed to shareholders on June 4, 2021.

ANGLE plc has announced a pivotal study revealing significant differences in EGFR mutations between circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients. Conducted by a research team from the University of Athens, this study highlights the importance of analyzing CTCs for better treatment decisions. The results indicate CTCs can provide real-time insights into tumor evolution and resistance, unlike ctDNA, which offers historical data. This research underscores the potential of liquid biopsies in safer, cost-effective monitoring of cancer progression.

ANGLE plc (OTCQX:ANPCY) has confirmed the completion of its response to the FDA's Additional Information Request regarding the Parsortix system, a liquid biopsy technology. The comprehensive response has been submitted as planned, and the company expects a regulatory decision during H2 2021. The Parsortix system aims to become the first FDA-cleared device for harvesting circulating tumor cells (CTCs), enhancing cancer diagnostics. The De Novo process entails inherent uncertainties regarding timing and success, yet ANGLE remains optimistic about the FDA's review outcome.